
Telix Pharmaceuticals Ltd
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Telix Pharmaceuticals develops radiopharmaceutical products used to diagnose and treat cancers, including prostate, kidney, and brain cancer, with its lead product being a PET imaging agent for prostate cancer detection.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Smith Darren CharltonGroup Chief Financial Officer | Buy | $20K | 2,071at $9.66 | Sep 7, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable TLX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.